Pipeline
Umoja’s VivoVec-driven pipeline is driving numerous near-term catalysts
Program
Preclinical
PHASE 1
PHASE 2
PHASE 3
UB-VV400
Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Preclinical
PHASE 1
PHASE 2
PHASE 3
Target
CD22
Rights
Global, ex-Greater China
In-Licensing Partner
IASO Biotherapeutics
NCT07735533
UB-VV500
Multiple Myeloma
Preclinical
PHASE 1
PHASE 2
PHASE 3
Target
BCMA x GPRC5D
Rights
Global
NCT07735546
UB-VV410
Lupus Nephritis
Preclinical
PHASE 1
PHASE 2
PHASE 3
Target
CD22
Rights
Global, ex-Greater China
In-Licensing Partner
IASO Biotherapeutics
NCT07109986
UB-VV1000
Solid Tumors
Preclinical
PHASE 1
PHASE 2
PHASE 3
Rights
Global
UB-VV111
Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia
Preclinical
PHASE 1
PHASE 2
PHASE 3
Target
CD19
Rights
Partnered
Out-Licensing Partner
AbbVie
NCT06528301
Multiple
Hematology
Preclinical
PHASE 1
PHASE 2
PHASE 3
Target
Undisclosed
Rights
Early development
Out-Licensing Partner
AbbVie
Multiple
Oncology
Preclinical
PHASE 1
PHASE 2
PHASE 3
Target
Undisclosed
Rights
Early development
Out-Licensing Partner
AbbVie
Expanded Access & Compassionate Use Policy
Umoja Biopharma is committed to developing innovative therapies through rigorous clinical research that address critical unmet needs. Currently, we do not offer access to our investigational therapies outside of clinical trials. We believe that participation in clinical trials is the most appropriate and equitable pathway for patients to access our investigational therapies until the safety and tolerability of each has been established and evaluated by regulatory authorities.
For more information about our ongoing studies, please visit clinicaltrials.gov. Search “Umoja” to find our clinical trials that may be recruiting. If you are a healthcare professional and would like more information on our investigational therapies, please send an inquiry to info@umoja-biopharma.com.
